DE-LYCRA
18.7.2022 11:02:08 CEST | Business Wire | Press release
The LYCRA Company , a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, is exhibiting its latest products for denim in person at Kingpins New York July 20-21 at Pier 36 in New York City. The company is showcasing samples made with LYCRA® ADAPTIV fiber , LYCRA® DUAL COMFORT technology , and its other industry-leading denim fibers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005067/en/
LYCRA® ADAPTIV fiber is a patent-pending revolutionary fiber that creates "one-size-fits-more" garments that adapt to fit different body shapes within a size. It also delivers a second-skin effect with excellent recovery and comfortable holding power.
"Consumers have different body types and this can impact garment fit and comfort," said Rita Ratskoff, senior strategic manager - denim, The LYCRA Company. "By offering greater shape tolerance, LYCRA® ADAPTIV fiber has the potential to reduce apparel returns and manufacturing waste by enabling the undercutting of patterns."
LYCRA® DUAL COMFORT technology combines the comfortable fit of stretch fabrics, the cool and dry comfort of moisture management, and LYCRA® T400® A EcoMade fiber, made from 68% sustainable resources including recycled and renewable content.
In The LYCRA Company booth, show visitors can also find innovative denim solutions from the LYCRA® XTRA LIFE™ brand's family of innovative denim solutions, including LYCRA® Anti-Slip fiber , LYCRA® dualFX® technology , and LYCRA® T400® fiber . They create long-lasting, durable garments that enable designers to develop heavy wash downs and distressed looks without fear.
For garment makers seeking sustainable offerings that reduce waste, denim that uses recycled materials will be on display. LYCRA® EcoMade fiber contains 20 percent recycled content, and COOLMAX® and THERMOLITE® EcoMade technologies are made from 100% textile waste.
"The LYCRA Company is committed to developing an innovative range of sustainable solutions made with renewable and recycled content that will enhance the performance of our customers' offerings while minimizing their environmental impact," said Jean Hegedus, sustainability director, The LYCRA Company. "We are excited to be in person at Kingpins again to promote our sustainable denim fibers that help reduce waste and set the stage for circularity."
Hegedus will join a panel discussion at Kingpins on July 21 at 11:30 a.m. entitled, "In Conversation: Denim Changemakers ." This panel brings together representatives from companies in the United Nations Conscious Fashion and Lifestyle Network, whose members are accelerating change in the denim sector. Participants will discuss industry commitments to increase sustainable practices and advance collective action to reach the United Nations' Sustainable Development Goals.
Kingpins New York is an invitation-only event for the denim community at Pier 36 / Basketball City in Manhattan. For more information, visit kingpinsshow.com/shows/new-york/.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA®, dualFX®, T400®, XTRA LIFE™, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005067/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom